Recent research conducted by Moshe C. Ornstein, MD, MA, and colleagues demonstrates that periodic sunitinib treatment breaks balance toxicity with clinical benefit and are a feasible option for patients with metastatic renal cell carcinoma (mRCC). In this prospective phase 2 trial, researchers treated patients who had undergone no prior systemic treatment with 50 mg sunitinib once per day for the first 28 days of a 42-day cycle. Unless toxicity or disease progression became unacceptable, patients were treated for four cycles.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Of the 37 patients who completed four cycles, 20 were eligible for subsequent intermittent therapy. Treatment interruptions were based on a reduction in tumor burden, and treatment was reinitiated upon tumor growth. Data from these patients show that extended breaks from treatment are feasible and result in clinical efficacy similar to that found in prior studies exploring sunitinib treatment in mRCC.
This trial is the first to investigate renal cell carcinoma treatment in which interruptions and reinitiations were based on tumor burden reduction and tumor growth.
To read the full article, visit the Journal of Clinical Oncology.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
